DBV (DBV) News
Follow DBV (DBV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
DBV Technologies reports third-quarter loss per share
EQUITY | Oct 28, 2026, 09:01 PM UTC
M
DBV Technologies Reports $64.5M Q3 Loss, Flags Going-Concern Risk
DBV Technologies reported a Q3 2026 net loss of $64.5 million and said substantial doubt exists about its ability to continue as a going concern. It had $165.7 million in cash as of September 30, with an estimated runway
EQUITY | Oct 28, 2026, 08:54 PM UTC
L
DBV Technologies submits BLA to FDA for VIASKIN Peanut Patch in ages 4—7, requests Priority Review
DBV Technologies submitted a Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch for children ages 4 through 7 and requested Priority Review.Key Highlights:Original SEC Filing: DBV Technologies S.A
REGULATION | Sep 30, 2026, 10:13 AM UTC
L
DBV Technologies Submitted BLA To U.S. FDA For Viaskin Peanut Patch In Children Aged 4-7 Years
DBV Technologies SA EURONEXT:DBV
REGULATION | Sep 30, 2026, 08:00 AM UTC
L
DBV Technologies (DBV) Files BLA for Viaskin Peanut Patch in Children 4—7
DBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN Peanut Patch in children aged 4—7 and requested Priority Review. The filing is supported by results from the VITESSE Phase 3 trial.Mat
REGULATION | Sep 29, 2026, 10:32 PM UTC
L
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Châtillon, France, September 29, 2026DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsDBV Technologies (Euronext: DBV — ISIN: FR00
REGULATION | Sep 29, 2026, 10:32 PM UTC
M
DBV patch-based peanut therapy reports long-term desensitization results
Epicutaneous immunotherapy for peanut allergy in children showed long-term efficacy and safety, with 68.2% tolerating full food challenges after three years.
EQUITY | Sep 09, 2026, 06:33 PM UTC
M
DBV skin-based peanut allergy therapy reports 68% three-year tolerance
DBV said a skin-based therapy for pediatric peanut allergy showed strong safety and convenience, with 68% of young children tolerating peanuts after three years, and it is pursuing regulatory progress.
EQUITY | Sep 09, 2026, 06:00 PM UTC
L
DBV Technologies to participate in upcoming September investor conferences
DBV Technologies says it will participate in upcoming September investor conferences, per a company announcement from Châtillon, France.
EQUITY | Sep 03, 2026, 08:37 PM UTC
L
DBV files voting rights and share totals as of Aug. 31, 2026
DBV provided total voting rights and total shares as of August 31, 2026 under AMF General Regulation Article 223-16. Market: NYSE Euronext Paris. ISIN: FR 0010417345.
EQUITY | Sep 02, 2026, 09:57 PM UTC